• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of International Medical Research >Effects of vitamin D on thyroid autoimmunity markers in Hashimoto’s thyroiditis: systematic review and meta-analysis
【24h】

Effects of vitamin D on thyroid autoimmunity markers in Hashimoto’s thyroiditis: systematic review and meta-analysis

机译：维生素D对Hashimoto甲状腺炎甲状腺自身免疫标志物的影响：系统评价与荟萃分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective To perform a meta-analysis of randomized controlled trials to evaluate the efficacy of vitamin D supplementation on thyroid autoimmunity markers in Hashimoto’s thyroiditis (HT). Methods This meta-analysis included randomized controlled clinical trials identified by a systematic search of electronic databases (PubMed?, MEDLINE?, EMBASE, The Cochrane Library, China National Knowledge Infrastructure) from inception to August 2020. All studies included patients with HT that received vitamin D supplementation irrespective of the doses administered or the duration of treatment. The primary and secondary outcome measures were thyroid peroxidase antibody (TPOAb) and/or thyroglobulin antibody (TGAb) titres. Results Eight studies ( n ?=?652) were included. There was significant heterogeneity between the studies. Using a random-effect model, vitamin D supplementation reduced TPOAb titre (standardized mean difference [SMD]: –1.11; 95% confidence interval [CI]: 1–1.92, –0.29) and TGAb titre (SMD: –1.12; 95% CI: –1.96, –0.28). A subgroup analysis demonstrated that vitamin D supplementation for &3 months resulted in a decrease in TPOAb titre (SMD: –1.66, 95% CI: –2.91, –0.41) but treatment ≤3 months was ineffective. Treatment with vitamin D _(3) decreased TPOAb titre (SMD: –1.48; 95% CI: –2.53, –0.42) whereas vitamin D did not. Conclusion These data suggest that vitamin D reduces autoantibody titre in patients with HT.
机译：目的对随机对照试验进行荟萃分析，以评估维生素D补充对哈西氏炎（HT）甲状腺自身免疫标志物的疗效。方法该荟萃分析包括通过系统搜索电子数据库（PubMed'，Medline，Embase，Cochrane图书馆，中国国家知识基础设施）所识别的随机对照临床试验从成立于2020年。所有的研究包括收到的HT患者维生素D无论施用剂量还是治疗持续时间，无论是否患有剂量。初级和二次结果措施是甲状腺过氧化物酶抗体（TPOAB）和/或甲基酚素抗体（TGAB）滴度。结果包括八项研究（n？=Δ652）。研究之间存在显着的异质性。使用随机效应模型，维生素D补充降低TPOAB滴度（标准化平均值[SMD]：-1.11; 95％置信区间[CI]：1-1.92，-0.29）和TGAB滴度（SMD：-1.12; 95％ CI：-1.96，-0.28）。亚组分析表明，维生素D补充了＆amp; 3个月导致TPOAB滴度减少（SMD：-1.66,95％CI：-2.91，-0.41），但治疗≤3个月无效。用维生素D _（3）治疗滴度下降（SMD：-1.48; 95％CI：-2.53，-0.42）而维生素D没有。结论这些数据表明，维生素D减少了HT患者的自身抗体滴度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号